Merck & Co.
A new study has found that cholesterol medicines known as "statins" may reduce the risk of strokes heart attacks and death by almost half when studied in patients with normal levels of cholesterol. With this finding at least 32 million people would be eligible for treatment. The drug studied is AstraZeneca Plc’s Crestor. The patients eligible for the study are those who have high amounts of a protein linked to inflammation.